16.75
price up icon4.10%   0.66
after-market Dopo l'orario di chiusura: 16.62 -0.13 -0.78%
loading
Precedente Chiudi:
$16.09
Aprire:
$15.86
Volume 24 ore:
1.28M
Relative Volume:
0.79
Capitalizzazione di mercato:
$1.44B
Reddito:
-
Utile/perdita netta:
$-44.84M
Rapporto P/E:
-35.64
EPS:
-0.47
Flusso di cassa netto:
$-44.23M
1 W Prestazione:
-2.95%
1M Prestazione:
+15.84%
6M Prestazione:
+56.40%
1 anno Prestazione:
+93.42%
Intervallo 1D:
Value
$15.75
$16.76
Intervallo di 1 settimana:
Value
$15.75
$18.90
Portata 52W:
Value
$8.77
$18.90

Ars Pharmaceuticals Inc Stock (SPRY) Company Profile

Name
Nome
Ars Pharmaceuticals Inc
Name
Telefono
858-771-9307
Name
Indirizzo
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
Name
Dipendente
160
Name
Cinguettio
Name
Prossima data di guadagno
2024-12-13
Name
Ultimi documenti SEC
Name
SPRY's Discussions on Twitter

Confronta SPRY con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
SPRY
Ars Pharmaceuticals Inc
16.75 1.44B 0 -44.84M -44.23M -0.47
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-03-07 Iniziato Scotiabank Sector Outperform
2025-02-10 Iniziato Oppenheimer Outperform
2024-08-20 Iniziato Cantor Fitzgerald Overweight
2024-08-13 Aggiornamento Raymond James Outperform → Strong Buy
2024-08-12 Reiterato Leerink Partners Outperform
2024-07-25 Iniziato Raymond James Outperform
2024-03-05 Aggiornamento Leerink Partners Market Perform → Outperform
2024-02-20 Aggiornamento William Blair Mkt Perform → Outperform
2023-09-20 Downgrade William Blair Outperform → Mkt Perform
2023-01-31 Iniziato Wedbush Outperform
2023-01-03 Iniziato William Blair Outperform
2022-12-13 Iniziato SVB Leerink Outperform
Mostra tutto

Ars Pharmaceuticals Inc Borsa (SPRY) Ultime notizie

pulisher
Jun 18, 2025

Learn to Evaluate (SPRY) using the Charts - news.stocktradersdaily.com

Jun 18, 2025
pulisher
Jun 18, 2025

ARS Pharmaceuticals | 6/18/25 - ktnv.com

Jun 18, 2025
pulisher
Jun 17, 2025

Asthma Market to Expand Significantly by 2034, States - openPR.com

Jun 17, 2025
pulisher
Jun 17, 2025

Asthma Market to Expand Significantly by 2034, States DelveInsight Report | GSK, AB Science, Areteia Therapeutics, ARS Pharma, AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharma, Genentech - Barchart.com

Jun 17, 2025
pulisher
Jun 15, 2025

ARS Pharmaceuticals signs agreement with ALK-Abelló A/S for neffy - MSN

Jun 15, 2025
pulisher
Jun 15, 2025

Jim Cramer on ARS Pharmaceuticals: “It’s a Great Flier” - Insider Monkey

Jun 15, 2025
pulisher
Jun 12, 2025

Jim Cramer Discussed These 16 Stocks Recently - Insider Monkey

Jun 12, 2025
pulisher
Jun 09, 2025

ARS Pharmaceuticals Earns Relative Strength Rating Upgrade - Investor's Business Daily

Jun 09, 2025
pulisher
Jun 06, 2025

Long Term Trading Analysis for (SPRY) - news.stocktradersdaily.com

Jun 06, 2025
pulisher
Jun 05, 2025

Bank of America Corp DE Has $1.70 Million Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

ARS Pharmaceuticals - WBFF

Jun 04, 2025
pulisher
Jun 03, 2025

Ameriprise Financial Inc. Buys 36,928 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

BNP Paribas Financial Markets Purchases New Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World

Jun 02, 2025
pulisher
Jun 02, 2025

ProShare Advisors LLC Buys 3,436 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World

Jun 02, 2025
pulisher
May 31, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $354,000 Stock Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World

May 31, 2025
pulisher
May 30, 2025

Deutsche Bank AG Increases Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World

May 30, 2025
pulisher
May 29, 2025

Neffy provides needle-free relief to those with allergic reactions - KOIN.com

May 29, 2025
pulisher
May 28, 2025

ARS brings relief to your whole home - KOIN.com

May 28, 2025
pulisher
May 27, 2025

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire

May 27, 2025
pulisher
May 27, 2025

ARS Pharmaceuticals Leadership Takes Stage at 3 Major Investment Conferences This June - Stock Titan

May 27, 2025
pulisher
May 26, 2025

(SPRY) Trading Advice - news.stocktradersdaily.com

May 26, 2025
pulisher
May 25, 2025

D. E. Shaw & Co. Inc. Decreases Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World

May 25, 2025
pulisher
May 23, 2025

ARS Pharmaceuticals: neffy - WCIV

May 23, 2025
pulisher
May 22, 2025

Exploring US High Growth Tech Stocks In May 2025 - simplywall.st

May 22, 2025
pulisher
May 22, 2025

Brent Saunders Sells 120,000 Shares of ARS Pharmaceuticals Inc (SPRY) - GuruFocus

May 22, 2025
pulisher
May 21, 2025

Expert Dr. Chase shares insights on Neffy for summer allergy season - KOKH

May 21, 2025
pulisher
May 19, 2025

FY2025 EPS Estimates for SPRY Cut by Cantor Fitzgerald - Defense World

May 19, 2025
pulisher
May 19, 2025

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Sold by The Manufacturers Life Insurance Company - Defense World

May 19, 2025
pulisher
May 19, 2025

Needle-Free Emergency Epinephrine Now Available for Pediatric Patients - Dermatology Advisor

May 19, 2025
pulisher
May 19, 2025

Leerink Partnrs Has Bearish Outlook for SPRY Q2 Earnings - Defense World

May 19, 2025
pulisher
May 19, 2025

William Blair Brokers Lower Earnings Estimates for SPRY - Defense World

May 19, 2025
pulisher
May 18, 2025

ARS Pharmaceuticals (NASDAQ:SPRY) Trading Up 10.8% – Still a Buy? - Defense World

May 18, 2025
pulisher
May 17, 2025

Price T Rowe Associates Inc. MD Reduces Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World

May 17, 2025
pulisher
May 17, 2025

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q1 2025 Earnings Call Transcript - MSN

May 17, 2025
pulisher
May 16, 2025

ARS Pharmaceuticals targets 80% commercial coverage for neffy in 2025 while expanding pediatric reach - MSN

May 16, 2025
pulisher
May 15, 2025

Ars Pharmaceuticals’ Neffy Launch Boosts Market Prospects - TipRanks

May 15, 2025
pulisher
May 15, 2025

ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Lags Revenue Estimates - MSN

May 15, 2025
pulisher
May 15, 2025

What You Need To Know About The ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analyst Downgrade Today - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

Analysts Have Just Cut Their ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Revenue Estimates By 15% - simplywall.st

May 15, 2025
pulisher
May 15, 2025

ARS Pharmaceuticals (SPRY) Reports Strong Start with Neffy Launc - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Dimensional Fund Advisors LP Has $2.07 Million Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World

May 15, 2025
pulisher
May 15, 2025

ARS Pharmaceuticals Reports Strong Q1 2025 Performance - TipRanks

May 15, 2025
pulisher
May 14, 2025

SPRY Reports Q1 Revenue Surpassing Expectations, Preps for Key M - GuruFocus

May 14, 2025
pulisher
May 14, 2025

ARS Pharmaceuticals (SPRY) Reports Strong Start with Neffy Launch in Q1 2025 - GuruFocus

May 14, 2025
pulisher
May 14, 2025

ARS Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat

May 14, 2025
pulisher
May 14, 2025

ARS Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 14, 2025
pulisher
May 14, 2025

Earnings call transcript: ARS Pharmaceuticals Q1 2025 revenue beats forecast - Investing.com Nigeria

May 14, 2025
pulisher
May 14, 2025

Transcript : ARS Pharmaceuticals, Inc., Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

ARS Pharmaceuticals Q1 2025 Earnings: Revenue Surpasses Estimates at $8.0M, EPS Misses at -$0.35 - GuruFocus

May 14, 2025
pulisher
May 14, 2025

ARS Pharmaceuticals Q1 Operating Income USD -37.177 Million - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

ARS PHARMACEUTICALS Earnings Results: $SPRY Reports Quarterly Earnings - Nasdaq

May 14, 2025

Ars Pharmaceuticals Inc Azioni (SPRY) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Ars Pharmaceuticals Inc Azioni (SPRY) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Karas Eric
Chief Commercial Officer
Jun 18 '25
Sale
16.00
15,000
240,000
7,696
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Capitalizzazione:     |  Volume (24 ore):